A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Phase 3
450
about 6.9 years
18+
50 sites in AZ, CA, CO +23
What this study is about
This trial is testing a treatment called anitocabtagene autoleucel compared to standard therapy for people with relapsed or refractory multiple myeloma. The goal is to see if the new treatment improves outcomes.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Anitocabtagene Autoleucel
- 2.Take Bortezomib
- 3.Take Carfilzomib
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
bortezomib, carfilzomib, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), daratumumab, dexamethasone, fludarabine, pomalidomide
injection (Injection), infusion, injection, ocular, oral (Oral Capsule)
Primary: Minimal Residual Disease (MRD) Complete Response (CR) Rate at 9 Months, Progression-Free Survival (PFS)
Secondary: CR Rate (CR/ Stringent Complete Response (sCR)), Change From Baseline in the EORTC - Multiple Myeloma Module (EORTC QLQ-MY20) Score, Change From Baseline in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score, Change From Baseline in the European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Score, Duration of Response (DOR), MRD-negative CR/sCR, Overall Response Rate (ORR), Overall survival (OS)
Oncology